PAVmed Inc (PAVM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $13.03M
Last updated: Nov 17, 2026 at 4:10 PM ET
PAVmed Inc (PAVM) Statistics
PAVmed (PAVM) has a market cap of $13.03M and an enterprise value of $23.60M. It kept -15847.30% of revenue as net income over the last 12 months. Revenue grew 410.34% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 81.06% above the market cap, as debt exceeds cash.
| Market Cap | $13.03M |
|---|---|
| Enterprise Value | $23.60M |
| Latest price (Nov 17, 2026) | $1.47 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 66.0x and 0.4x. Its year-end P/S ranged from 2.6x to 113.7x from 2022 to 2024.
| P/S Ratio | 66.0x |
|---|---|
| Forward P/S | 56.1x |
| P/B Ratio | 0.4x |
Price Statistics
The stock is down 84.69% over 52 weeks and trades 46.15% below its 50-day average.
| Beta (1Y) | 1.09 |
|---|---|
| 52-Week Change | -84.69% |
| 1-Month Change | -34.67% |
| 3-Month Change | -71.18% |
| 6-Month Change | -77.03% |
| 5-Year Change | -99.92% |
| 10-Year Change | -99.96% |
| Total Return (1Y) | -84.69% |
| Total Return (3Y CAGR) | -75.34% |
| Total Return (5Y CAGR) | -76.09% |
| Return vs SPY (1Y) | -98.66% |
| Max Drawdown (1Y) | -88.89% |
| Max Drawdown (3Y) | -99.04% |
| Sharpe Ratio (1Y) | -1.72 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $2.73 |
| 200-Day Average | $6.15 |
| 52-Week Range | $1.17 to $12.70 |
| RSI (14 Days) | 33.5 |
| Average Volume (20 Days) | 25.63K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.41x current liabilities, and total debt is 0.52x shareholder equity.
| Current Ratio | 0.41x |
|---|---|
| Quick Ratio | 0.41x |
| Debt / Equity | 0.52x |
| Interest Coverage | -5.84x |
Returns and Efficiency
Return on invested capital is -38.04% over the last 12 months, against a 5-year average of -4.24%.
| Return on Equity (ROE) | -85.43% |
|---|---|
| Return on Assets (ROA) | -66.62% |
| Return on Invested Capital (ROIC) | -38.04% |
| Return on Capital Employed (ROCE) | -175.76% |
| ROA (5Y Average) | -81.75% |
| ROIC (5Y Average) | -4.24% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 6.30x |
Scores
PAVM has an Altman Z-Score of -13.12, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -13.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $148.00K over the last 12 months.
| Revenue | $148.00K |
|---|---|
| Revenue Growth (YoY) | +410.34% |
| Gross Profit | -$315.00K |
| Operating Income | -$28.59M |
| Pretax Income | -$23.45M |
| Net Income | -$23.45M |
| EBITDA | -$19.98M |
| EBIT | -$20.06M |
| Reported EPS (TTM) | -$2.97 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.96% of the $35.21M in total assets.
| Cash and Equivalents | $3.63M |
|---|---|
| Total Debt | $14.20M |
| Net Debt | $10.56M |
| Net Debt Per Share | $1.59 |
| Working Capital | -$14.11M |
| Shareholder Equity | $27.45M |
| Book Value Per Share | $3.54 |
| Total Assets | $35.21M |
| Total Liabilities | $25.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $57.00K of capital spending, operating cash flow left -$4.48M of free cash flow.
| Operating Cash Flow | -$4.42M |
|---|---|
| Capital Expenditures | $57.00K |
| Free Cash Flow | -$4.48M |
| FCF Per Share | -$0.56 |
| Depreciation and Amortization | $76.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -19314.19%.
| Gross Margin | -212.84% |
|---|---|
| Operating Margin | -19314.19% |
| Pretax Margin | -15847.30% |
| Net Margin | -15847.30% |
| EBITDA Margin | -13500.00% |
| EBIT Margin | -13551.35% |
| FCF Margin | -3024.32% |
Dividends and Yields
PAVM does not pay a dividend. Its free cash flow yield is -45.86%.
| FCF Yield | -45.86% |
|---|---|
| Buyback Yield | -77.88% |
| Shareholder Yield | -77.88% |
Stock Splits
The last split was a 1-for-30 reverse split on Jan 2, 2026.
| Last Split Date | Jan 2, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 9 similar companies, PAVM has the highest P/S and the 3rd highest ROIC.
P/S RatioPeer median 0.6x
ROICPeer median -147.05%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.79%
| P/S Ratio | 66.0x vs 0.6x median |
|---|---|
| ROIC | -38.04% vs -147.05% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +410.34% vs +7.79% median |
Analyst Forecast
Consensus estimates put revenue growth at 190.70% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +190.70% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PAVM
What is PAVM's market cap?
PAVmed has a market cap of $13.03M. Its enterprise value, which adds debt and subtracts cash, is $23.60M.
How many shares of PAVM are outstanding?
PAVmed has 6.64M shares outstanding.
Does PAVM pay a dividend?
No. PAVmed does not pay a dividend.
How much debt does PAVM have?
PAVmed has $14.20M of total debt and $3.63M of cash and equivalents, a net debt position of $10.56M.
PAVM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors